The metabolic pathways for five transmitters in the basal ganglia are briefly described; the results of determinations of their concentrations, of their rate-limiting enzymes and of their degradation products are summarized.
Introduction
How our understanding of Nature advances may be pictured in terms of a sequence of boxes in which new knowledge on a particular topic can be stored, at first appropriately but eventually with decreasing appropriateness until finally the box breaks apart and a new box-a new way of looking at the topicis set up. This remains acceptable for a time until eventually it also breaks down-and so on.
A new box for Parkinson's disease was built with dramatic speed about 15 years ago, when it was found that the distribution of dopamine in the brain did not simply parallel that of noradrenaline (Bertler, 1961) . This suggested that dopamine was not merely a precursor of noradrenaline but a transmitter in its own right. Furthermore, the strikingly high dopamine concentrations in the striatum pointed to a role in the control of movement. Almost concurrently Ehringer and Hornykiewicz (1960) reported that dopamine was low in Parkinson's disease not only in the striatum but also in the substantia nigra. This linked the new biochemical findings with classical neuropathology because loss of melanin-containing cells in the substantia nigra had long been recognized as a characteristic of Parkinson's disease (Greenfield and Bosanquet, 1953) . These observations were all tied together when Anden, Strombom and Svensson (1964) showed that causing lesions in the substantia nigra of laboratory animals led to a decrease of dopamine in the striatum.
So here was a very attractive conceptual box for Parkinson's disease in which a lesion in the substantia nigra led to a dopamine deficit in the striatum-hence to a movement disturbance. This led to a major therapeutic advance-the L-dopa treatment, but the conceptual box almost immediately started to crack-it was no longer the right shape to hold all our knowledge of Parkinson's disease.
For example, Parkinson's disease did not result when substantia nigra lesions were made in laboratory animals (Mettler, 1964) . Also, at the same time that the striatal dopamine defect in the disease was found, evidence was obtained of less striking but considerable defects of two other transmitters, noradrenaline (Ehringer and Hornykiewicz, 1960) and 5-hydroxytryptamine (Bernheimer, Birkmayer and Hornykiewicz, 1961) . These defects were found not only in the basal ganglia but also in the other regions. Information on disturbances of other transmitters has accumulated so that it is now difficult to consider Parkinson's disease exclusively in terms of basal ganglia dopamine metabolism and merely to mention other transmitter abnormalities in passing.
This paper will therefore deal with dopamine and other transmitters in the basal ganglia and elsewhere and with their metabolism and significance in Parkinson's disease.
Transmitters in the basal ganglia Table 1 briefly indicates some of the more important aspects of the biochemistry of five transmitters, dopamine (DA), noradrenaline (NA), 5-hydroxytryptamine (5HT), acetylcholine (ACh) and yaminobutyric acid (GABA). Complete metabolic pathways and relevant literature references are given elsewhere (Curzon, 1976 (Table 3) found marked deficiencies of DA and of its metabolite homovanillic acid in the parkinsonian basal ganglia. The metabolite is proportionately rather less decreased than the parent amine. A similar difference between the DA and homovanillic acid deficits was also found when these were plotted against the extent of the lesion in the substantia nigra . Thus, as the size of the lesion increases, dopamine level decreases, but its turnover rate increases suggesting some kind of compensatory mechanism. Comparable results have been obtained in the rat by Agid, Javoy and Glowinski (1973) , who showed that a unilateral but partial lesion of the rat substantia nigra led to accelerated DA synthesis in surviving neurones of the damaged side of the brain.
In parkinsonian patients, striatal DA is already markedly decreased even when symptoms are still mild (Bernhcimer et al., 1973) . This agrees with the concept that in early stages of the disease compensatory changes lead to the surviving neurones becoming functionally more effective. Another kind of compensatory change may also occur so that postsynaptic response to DA is enhanced. Thus, unilateral destruction of striatal DA-containing tracts in the rat increases responsiveness of dopamine receptors on the damaged side. This can be revealed by giving the DA agonist apomorphine as this causes circling movements away from the lesioned side (Ungerstedt et al., 1973) . Such effects are usually interpreted as indicating a direct increase of receptor sensitivity, although this is not yet proved to be their mechanism, i.e. striatal material from lesioned animals has not been clearly shown to synthetize more cyclic AMP than material from unlesioned animals when incubated with DA. Table 4 lists various possible states of dopaminergic neurones in the parkinsonian brain. Clinically manifest Parkinsonism appears to represent a late stage in the disease process in which these compensatory changes are no longer sufficient to maintain normal neuronal function (Bernheimer et al., 1973) .
As the DA defect follows the degeneration of the whole DA-containing nigrostriatal presynaptic tract, the intraneuronal enzymes required for dopamine synthesis are also markedly diminished (Table 5) . Thus, the rate-limiting enzyme tyrosine hydroxylase is decreased in regions rich in dopamine terminals. It is, however, also decreased in the hippocampus which is poor in DA but has considerable amounts of NA synthesis which also depends on tyrosine hydroxylase (Table 1) . Dopa decarboxylase, an intraneuronal enzyme responsible for the final step in DA synthesis but which is not rate-limiting, is also strikingly low in the parkinsonian brain in nigrostriatal regions. There is at least a suggestion that it is low in other regions including the raphe nuclei-which contain cell bodies of 5HT neurones. This could reflect a deficiency of the enzyme equipment for 5HT synthesis because the decarboxylase here is able to act not only on the 5HT precursor, 5-hydroxytryptophan, but also on dopa.
Tyrosine hydroxylase and the decarboxylating enzyme are both presynaptically localized. A completely different picture emerges when the enzymes required for catecholamine destruction are considered (Table 6 ). Thus, catechol-O-methyltransferase and monoamineoxidase activities appear (4) completely normal. The former enzyme occurs postsynaptically and the latter both in glial cells and presynaptically but only a small fraction occurs specifically in DA-containing neurones.
Other transmitter abnormalities Data in Table 7 suggest considerable deficiencies of NA and 5HT not only in the basal ganglia but also elsewhere in the brain. Defective NA synthesis is hardly surprising as lesions occur not only in the parkinsonian substantia nigra where the dopamine cell bodies are largely located but also in the locus caerulus (Greenfield and Bosanquet, 1953 ) which contains the cell bodies of the NA-containing tracts. Defective brain 5HT metabolism is indicated by many reports of low 5-hydroxyindoleacetic acid concentration in the CSF. In particular, Guldberg et al. (1967) found low levels in the lateral ventricular CSF in which concentrations are more closely related to brain metabolism than in the lumbar CSF, where this substance is more commonly determined.
Furthermore, there is evidence for a rather widespread deficiency of glutamate decarboxylase the rate-limiting enzyme for GABA synthesis (Table 8) . Deficiency of this enzyme has been given more emphasis in Huntington's chorea than in Parkinson's disease and it is interesting to compare results in the two disorders. In Huntington's chorea there is a massive deficit but apparently restricted to parts of the brain with a major dopamine innervation. Thus, the cortex as a whole contains relatively little DA and here glutamate decarboxylase is normal. In Parkinson's disease, the enzyme deficiency is considerable, not restricted to DA-rich parts of the brain and (unlike in Huntington's chorea) it occurs together with massively decreased synthesis of DA and decreases of other transmitters. Within the basal ganglia the defect is most marked in the substantia nigra and the pallidum.
Available data on cholineacetyltransferase, the rate-limiting enzyme for ACh synthesis, show some conflict (Table 9) . Results from Lloyd et al. (1975b) suggest deficiency which seems most marked in the substantia nigra and in the pallidum (Table 8) . However, their results differ from those of McGeer and McGeer (1976) who find normal values in the caudate and significantly high ones in the nucleus accumbens. These differences could be due to differences in patient selection. The many problems involved in interpreting transmitter amine data obtained on post-mortem material should also be borne in mind.
Discussion
Findings suggest that Parkinson's disease is associated not only with defective DA synthesis in the basal ganglia but also with defects in synthesis of a number of other transmitters. Many questions therefore arise. What is the significance of the DA defect in particular regions? Are the other transmitter defects sequels to that of DA or does an unknown, more primal disturbance lead to all the abnormalities? What are the neuronal interrelationships? What part do the various transmitter defects play in the development of symptoms? We can only partially answer or comment on these questions at present.
One topic which is generating much interest is the DA defect in the nucleus accumbens suggested by the low tyrosine hydroxylase activity (Table 5) . Various drug experiments in animals suggest that this may have a specific role. For example, using rats rendered immobile by depleting their brain amines with reserpine, Jackson, Anden and Dahlstrom (1975) found that DA injected unilaterally into the nucleus accumbens increased co-ordinated motor activity while injection into the caudate caused stereotyped movement, such as gnawing.
Coming to the other transmitters, it now seems that NA depletion has a role in reserpine rigidity and therefore possibly in human Parkinsonism. Thus Marsden et al. (1974) found that reversal of reserpine rigidity in mice by dopa was prevented by a NA receptor antagonist phenoxybenzamine but not by the DA antagonist pimozide. Work by suggests that both catecholamines are required for reversal of reserpinization as they found reversal was partial with the DA agonist apomorphine and increased further by the noradrenaline agonist clonidine. Cools and Janssen (1974) suggested that 5HT is required for post-synaptic DA response and that therefore the defective 5HT synthesis in Parkinsonism could be important. They showed that stereotyped movements in the rat after systemic injection of the DA agonist apomorphine and the contralateral turning after injecting DA into the caudate were both prevented by injection of procaine into one of the 5HT cell body-containing regionsthe nucleus linearis intermedius. This may explain some work indicating that dopa tended to be ineffective in Parkinson's disease patients who had particularly low CNS 5HT as indicated by low lumbar CSF 5-hydroxyindole acetic acid, but rather normal DA metabolism (for parkinsonian patients) as indicated by only moderately low CSF homovanillic acid (Gumpert, Sharpe and Curzon, 1973) . It is also possible that low 5HT synthesis plays a part in the depression often associated with Parkinson's disease.
The GABA defect can be considered in terms of the interrelationship between dopamine and GABA neurones in the basal ganglia. As well as the nigrostriatal dopaminergic system with cell bodies in the substantia nigra and terminals in the striatum, a striato-nigral gabaminergic system exists with cell bodies in the striatum and terminals in the substantia nigra. These terminals are mostly near the zona compacta of the substantia nigra (Kananzawa et al., 1973) which contains the dopamine cell bodies. When GABA neurones fire they very probably inhibit the firing of dopamine neurones. Thus iontophoresis of GABA into the substantia nigra inhibits dopamine firing and this inhibition can be prevented by the GABA antagonist picrotoxin (Crossman, Walker and Woodruff, 1973) . Furthermore, injection of picrotoxin into the substantia nigra causes behavioural changes like those mediated by DA (Tarsy et al., 1975 (Cools and Janssen, 1974; Cools and Van Rossum, 1976) . If a GABA defect in Parkinson's disease leads to decreased inhibition of firing of surviving DA neurones then this could in turn lead to increased turnover rate of the DA contained in them and hence to the increased ratio of homovanillic acid to DA (Table 3 ). Other mechanisms for this change are also possible.
Evidence of abnormal ACh synthesis in Parkinson's disease (Table 9 ) is harder to interpret. McGeer et al. (1973) found that lesions between the substantia nigra and striatum do not alter choline acetyltransferase activity in either region, which is evidence against major ACh tracts between the substantia nigra and striatum. More recently, some DA terminals in the striatum were shown to be in contact with dendrites and spikes of ACh-containing neurones (Hatori et al., 1976) . Interaction between DA and ACh neurones is consistent with pharmacological results as the DA-receptor antagonist chlorpromazine increases ACh output from the striatum (Stadler et al., 1973) . This points to the possibility that dopamine normally inhibits cholinergic neurones and may explain the frequent exhibition of excessive cholinergic activity by parkinsonian patients despite the defective ACh synthesis in most basal ganglia regions found by Lloyd et al. (1975b) . A rather different explanation of the increased cholinergic activity has been proposed (Spehlmann and Stahl, 1976) involving the sprouting of cholinergic neurones to replace lost DA terminals. Perhaps this explains the high choline acetyltransferase activity found in the nucleus accumbens in Parkinson's disease (McGeer and McGeer, 1976 (Garelis et al., 1974; Curzon, 1976) there are major restrictions on the interpretation of data obtained on CSF. A hopeful but fairly distant possibility is that gradually emerging correlation of post-mortem biochemical studies on brain material with previous symptoms will lead to the prediction of therapeutic manoeuvres likely to help similarly affected patients.
